AU4081493A - 8-substituted anthines as phosphodiesterase inhibitors - Google Patents

8-substituted anthines as phosphodiesterase inhibitors

Info

Publication number
AU4081493A
AU4081493A AU40814/93A AU4081493A AU4081493A AU 4081493 A AU4081493 A AU 4081493A AU 40814/93 A AU40814/93 A AU 40814/93A AU 4081493 A AU4081493 A AU 4081493A AU 4081493 A AU4081493 A AU 4081493A
Authority
AU
Australia
Prior art keywords
formula
compound
pharmaceutically acceptable
group
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40814/93A
Other languages
English (en)
Inventor
Ashley Edward Fenwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU4081493A publication Critical patent/AU4081493A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU40814/93A 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors Abandoned AU4081493A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9210839 1992-05-21
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds

Publications (1)

Publication Number Publication Date
AU4081493A true AU4081493A (en) 1993-12-13

Family

ID=10715834

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40814/93A Abandoned AU4081493A (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors

Country Status (10)

Country Link
EP (1) EP0641344A1 (enrdf_load_stackoverflow)
JP (1) JPH07506591A (enrdf_load_stackoverflow)
CN (1) CN1094046A (enrdf_load_stackoverflow)
AU (1) AU4081493A (enrdf_load_stackoverflow)
CA (1) CA2136196A1 (enrdf_load_stackoverflow)
GB (1) GB9210839D0 (enrdf_load_stackoverflow)
MX (1) MX9302957A (enrdf_load_stackoverflow)
TW (1) TW277062B (enrdf_load_stackoverflow)
WO (1) WO1993023401A1 (enrdf_load_stackoverflow)
ZA (1) ZA933494B (enrdf_load_stackoverflow)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
EP1043324B1 (en) 1997-11-12 2004-06-16 Mitsubishi Chemical Corporation Purine derivatives and medicine containing the same as the active ingredient
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
ATE254616T1 (de) * 1999-05-11 2003-12-15 Mitsubishi Chem Corp Dihydrat eines purinderivates, medikamente die dieses als aktiven wirkstoff enthalten und zwischenprodukte zu dessen herstellung
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
EP1208100B1 (en) * 1999-08-31 2003-04-02 Vanderbilt University Selective antagonists of a2b adenosine receptors
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60226615D1 (enrdf_load_stackoverflow) 2001-08-28 2008-06-26 Schering Corp
WO2003042216A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
EP1521584A1 (en) 2002-06-17 2005-04-13 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
KR20050026546A (ko) 2002-07-29 2005-03-15 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 수용체 작용제를 이용한 심근 관류 조영
ATE363483T1 (de) 2003-07-31 2007-06-15 Schering Corp Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
EP1802317A2 (en) 2004-10-20 2007-07-04 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2033922T3 (es) * 1986-08-28 1993-04-01 Sandoz Ag Procedimiento para preparar nuevos derivados de xantina.
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
ATE194345T1 (de) * 1990-12-21 2000-07-15 Beecham Group Plc Xanthinderivate

Also Published As

Publication number Publication date
EP0641344A1 (en) 1995-03-08
GB9210839D0 (en) 1992-07-08
MX9302957A (es) 1994-05-31
CA2136196A1 (en) 1993-11-25
ZA933494B (en) 1994-03-01
TW277062B (enrdf_load_stackoverflow) 1996-06-01
WO1993023401A1 (en) 1993-11-25
JPH07506591A (ja) 1995-07-20
CN1094046A (zh) 1994-10-26

Similar Documents

Publication Publication Date Title
AU4081493A (en) 8-substituted anthines as phosphodiesterase inhibitors
US5981535A (en) Substituted xanthines and their use in the treatment of cerebrovascular disorders and other diseases
US5409934A (en) Xanthine derivatives
AU653364B2 (en) Xanthine derivatives
AU717913B2 (en) Xanthines and their therapeutic use
JP3504234B2 (ja) ホスホジエステラーゼｉｖ阻害活性を有するプリン誘導体
JP2004002467A (ja) 鏡像異性体ヒドロキシル化キサンチン化合物
IE913351A1 (en) Novel compounds
JPH10508032A (ja) アリールチオキサンチン類
EP0545413B1 (en) Trans cyclopentanyl purine analogs useful as immunosuppressants
HK1012360B (en) Xanthinederivatives, process for their preparation and their pharmaceutical use
HK1012360A (en) Xanthinederivatives, process for their preparation and their pharmaceutical use